Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,093.00+0.25%ETH$2,517.02+2.81%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
DE

NASDAQ · DERM

Journey Medical Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

$7.09

Up+$0.14 (+1.97%)

Updated Sep 11, 2026, 9:59 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
178.63M
P/E ratio
-20.66
Dividend yield
0.00%
52-week range
$4.31 – $9.56
Volume
265.19K
Avg. volume
167.08K

Price performance

DERM price history

1M range · 0 trading sessions · Daily adjusted prices

DERM does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest DERM news

The latest Smart Investors Daily articles mentioning DERM.

Stock researchCompany · Overview

DERM research

Overview

Company profile and research snapshot.

Company profile

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.00
Implied upside
—
Analysts
10
DERM recent ratings
DateFirmRatingTarget
Aug 13, 2026B. Riley SecuritiesBuy—
Mar 26, 2026HC Wainwright & Co.Buy—
Aug 25, 2025HC Wainwright & Co.Buy—
Aug 13, 2025Lake StreetBuy—
Jul 30, 2025B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories

The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, greater patient awareness and demand for safer, non-antibiotic treatments. Advanced therapies—including topical ivermectin, azelaic acid, minocycline foam, modified-release doxycycline, biologics and microbiome-based solutions—are reshaping care. Growth across North America, Europe and Asia-Pacific is also supported by dermatology R&D, innovative drug delivery and

Yahoo · Aug 19, 2026

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Nirav Jhaveri, Chief Financial Officer Nirav Jhaveri, Chief Financial Officer Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Com

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By